Cyient develops Urban Forestry Land in Hyderabad equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, May 14, 2021 /PRNewswire/ PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of
Riverside adds on PPM Advisory Group to Red Nucleus platform
Riverside adds on PPM Advisory Group to Red Nucleus platform
Print
The Riverside Co. has acquired PPM Advisory Group and its subsidiary, OrtleyBio, as the latest add-on for its Red Nucleus platform company.
Financial terms of the deal were not disclosed.
PPM, based in Chatham, N.J., provides scientific operations and communications services to global biopharmaceurtical companies with a focus on oncology and hematology therapeutic areas.
The transaction marks the fifth add-on deal related to the platform since an initial investment in December 2019. The other acquisitions are Pyxa Systems (DirectusPRO), LSTI, INVIVO Communications and iTakeControl.
Red Nucleus Acquires PPM Advisory Group and OrtleyBio
Share Article
Red Nucleus boosts its service offering by adding a leading provider of medical affairs and commercialization services
Red Nucleus Clients will benefit from the expanded expertise and services the acquisition creates. Red Nucleus CEO Ian Kelly YARDLEY, Pa. (PRWEB) April 15, 2021 Red Nucleus (“RN”), a premier provider of learning, performance, and process solutions for the life sciences industry, announced that it has acquired PPM Advisory Group and OrtleyBio (collectively “PPM”), a leading provider of scientific operations and communications services to biopharmaceutical companies and brands, with its primary focus in oncology and hematology therapeutic areas.
Riverside acquires iTakeControl of Pennsylvania as latest add-on for Red Nucleus platform
Print
The Riverside Co. has acquired iTakeControl, a Malvern, Pa.-based provider of clinical operations and medical affairs technology and services focused on rare disease and specialty pharma, as an add-on to its Red Nucleus platform company.
Terms of the deal were not disclosed.
The transaction marks the fourth add-on deal related to the platform since an initial investment in December 2019. This partnership will provide Red Nucleus with a new, differentiated SaaS technology product undergoing significant growth in the marketplace, said Peter Tsang, Riverside co-chief investment officer for Riverside Capital Appreciation Fund, in a statement. Working with the ITC team, we plan to expand our suite of software products with the company s virtual clinical software platform and leverage Red Nucleus learning expertise to deliver education programs for clinical trial patients via ITC s pl